Tags : Advanced Hepatocellular Carcinoma

Takeda Report Submission of NDA to MHLW for Cabometyx (cabozantinib)

Shots: The NDA is based on two clinical studies, P-III CELESTIAL (XL184-309) & P-II Cabozantinib-2003 study assessing Cabometyx in patients with advanced HCC prior treated with systemic therapy In 2017, Exelixis and Takeda collaborated for Cabometyx in Japan, under which Exelixis will receive ~$10M milestones following the NDA submission for HCC, expected to receive in […]Read More